Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT06801067

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Led by Memorial Sloan Kettering Cancer Center · Updated on 2025-12-02

15

Participants Needed

7

Research Sites

104 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The purpose of this study is to find out whether SER-155 may be a safe first treatment that causes few or mild side effects for people due to irEC.

CONDITIONS

Official Title

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age > 18 years
  • Received immune checkpoint inhibitor treatment within 180 days before screening
  • Grade 2 to 3 diarrhea likely related to immunotherapy, with or without mild colitis symptoms
  • Able to swallow oral medication
  • Willing to use effective contraception if of childbearing potential for 30 days after last dose of SER-155
  • Provide written informed consent and comply with study procedures
Not Eligible

You will not qualify if you...

  • Active gastrointestinal infection causing diarrhea
  • Received immunosuppressive therapy for irEC, including corticosteroids or specific biologics
  • Severe colitis symptoms such as severe abdominal pain or peritoneal signs
  • Hospitalized for immunotherapy-related enterocolitis
  • Taking prednisone over 10 mg daily for non-gastrointestinal immune side effects at screening
  • Pre-existing inflammatory bowel diseases or microscopic colitis
  • Pregnant or breastfeeding
  • Require ongoing antibacterial antibiotics
  • Severe neutropenia (ANC < 500 cells/mm³) at screening
  • Use of investigational diarrhea or microbiome treatments within 30 days prior to enrollment
  • Known allergy or intolerance to oral vancomycin
  • Unable to follow study protocol
  • Any condition that may increase risk or interfere with study results as judged by investigator

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 7 locations

1

Memoral Sloan Kettering at Basking Ridge (Limited Protocol Activities)

Basking Ridge, New Jersey, United States, 07920

Actively Recruiting

2

Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, United States, 07748

Actively Recruiting

3

Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, United States, 07645

Actively Recruiting

4

Memorial Sloan Kettering Suffolk-Commack (Limited protocol activity)

Commack, New York, United States, 11725

Actively Recruiting

5

Memorial Sloan Kettering Westchester (Limited Protocol Activities)

Harrison, New York, United States, 10604

Actively Recruiting

6

Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, United States, 10065

Actively Recruiting

7

Memorial Sloan Kettering Nassau (Limited protocol activities)

Rockville Centre, New York, United States, 11553

Actively Recruiting

Loading map...

Research Team

D

David Faleck, MD

CONTACT

M

Michael Postow, MD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

A Study of SER-155 to Treat Diarrhea in People on Immunotherapy | DecenTrialz